Atrial Fibrillation Ablation in Patients with Arrhythmia-Induced Cardiomyopathy: A Prospective Multicentre Study
ESC Heart Failure · 2023
DOI: 10.1002/ehf2.14448 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Teba González-Ferrero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Cardiomyopathies, Ventricular Function, Left. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Aims
This study aims to investigate the clinical and biochemical characteristics of patients with atrial fibrillation (AF) referred for ablation who develop arrhythmia-induced cardiomyopathy (AiCM) as well as their long-term outcomes after catheter ablation (CA). Methods and results A prospective multicentre study was conducted on consecutive AF patients who underwent CA. AiCM was defined as the development of heart failure in the presence of AF and an improvement of left ventricular fraction by at least 10% at 6 months after ablation. A subgroup of patients underwent peripheral and left atrial blood samples [galectin-3, fatty acid-binding protein 4 (FABP4), and soluble receptor for advanced glycation end products (sRAGE)] at the time of the procedure. Of the 769 patients who underwent AF ablation, 135 (17.56%) met the criteria for AiCM. Independent predictors of AiCM included persistent AF, male gender, left atrial volume, QRS width, active smoking, and chronic kidney disease (CKD). Biomarker analysis revealed that sRAGE, FABP4, and galectin-3 levels were not predictive of AiCM development nor did they differ between groups or predict recurrence. There were no differences in AF recurrence between patients with and without AiCM (30.83% vs. 27.77%; P = 0.392) during a median follow-up of 23.83 months (inter-quartile range 9–36).
Conclusions
In the subset of patients referred for AF ablation, the development of AiCM was associated with persistent AF and CKD. Biomarker analysis was not different between groups nor predicted recurrence. Patients with AiCM benefited from ablation, with a significant improvement in left ventricular ejection fraction and similar AF recurrence rates to those without AiCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela, 15706, A Coruña, Spai…
- CIBERCV, Carlos III Health Institute, Madrid, Spain.
- Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium.
- Cardiovascular Research, GENCOR, University of Antwerp, Antwerp, Belgium.
- Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland.
ORCID-Profile: Teba González-Ferrero
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
González-Ferrero, T., Bergonti, M., López-Canoa, J. N., Arias, F. G., Eiras Penas, S., Spera, F., González-Maestro, A., Minguito-Carazo, C., Martínez-Sande, J. L., González-Melchor, L., García-Seara, F. J., Fernández-López, J. A., Álvarez-Castro, E., González-Juanatey, J. R., Heidbuchel, H., Sarkozy, A., & Rodríguez-Mañero, M. (2023). Atrial Fibrillation Ablation in Patients with Arrhythmia-Induced Cardiomyopathy: A Prospective Multicentre Study. ESC Heart Failure. https://doi.org/10.1002/ehf2.14448
Vancouver
González-Ferrero T, Bergonti M, López-Canoa JN, Arias FG, Eiras Penas S, Spera F, et al. Atrial Fibrillation Ablation in Patients with Arrhythmia-Induced Cardiomyopathy: A Prospective Multicentre Study. ESC Heart Failure. 2023. doi:10.1002/ehf2.14448
BibTeX
@article{GonzlezFerrero2023,
author = {González-Ferrero, Teba and Bergonti, Marco and López-Canoa, José Nicolás and Arias, Federico García-Rodeja and Eiras Penas, Sonia and Spera, Francesco and González-Maestro, Adrián and Minguito-Carazo, Carlos and Martínez-Sande, José Luis and González-Melchor, Laila and García-Seara, Francisco Javier and Fernández-López, Jesús Alberto and Álvarez-Castro, Ezequiel and González-Juanatey, José Ramón and Heidbuchel, Hein and Sarkozy, Andrea and Rodríguez-Mañero, Moisés},
title = {Atrial Fibrillation Ablation in Patients with Arrhythmia-Induced Cardiomyopathy: A Prospective Multicentre Study},
journal = {ESC Heart Failure},
year = {2023},
doi = {10.1002/ehf2.14448}
}
EUVIMED